As a valid tumor marker, vascular endothelial growth factor 165 (VEGF165) is an effective therapeutic target for anticancer treatments. Aptamers hold great promise for the development of anti-VEGF strategies. In this study, anti-VEGF165 ssDNA aptamers were screened using a semirational design and a multilevel screening strategy.
View Article and Find Full Text PDFSheng Wu Gong Cheng Xue Bao
November 2021
Vascular endothelial growth factor (VEGF165) is a highly specific vascular endothelial growth factor that can be used to treat many cardiovascular diseases. The development of anti-tumor drugs and disease detection reagents requires highly pure VEGF165 (at least 95% purity). To date, the methods for heterologous expression and purification of VEGF165 require multiple purification steps, but the product purity remains to be low.
View Article and Find Full Text PDFBackground: Chronic pulmonary heart disease (CPHD) is a common type of heart disease. In China, chronic obstructive pulmonary disease (COPD) is one of the main causes of CPHD. At present, there is no specific therapy for COPD-induced CPHD, so it is of great importance to identify a new therapy for CPHD.
View Article and Find Full Text PDFBackground: Traditional Chinese medicine (TCM) tongue diagnosis plays an important role in differentiation of symptoms because the tongue reflects the physiological and pathological condition of the body. The automatic tongue diagnosis system (ATDS), which noninvasively captures tongue images, can provide objective and reliable diagnostic information. Chronic kidney disease (CKD) currently is an important global public health problem and contributor to morbidity and mortality from non-communicable diseases.
View Article and Find Full Text PDFBackground: Pulmonary hypertension (PH) is a commonly observed complication of chronic obstructive pulmo-nary disease (COPD) which may lead to poor prognosis of the disease. The present study aims to explore the roles of circulating miR-210 for the early diagnosis of COPD included PH.
Methods: We included 80 patients with COPD including PH, 80 patients with COPD but without PH, and 80 healthy subjects as the study population.